EXPERT PANELISTS

EDWIN CHAPMAN, MD DISTRICT OF COLUMBIA SUBOXONE TREATMENT PROGRAM

For over 35 years, EDWIN C. CHAPMAN, Sr., M.D. has maintained an active private practice in general Internal Medicine located in Northeast Washington, D.C concentrating on chronic diseases including diabetes, hypertension, and cardiovascular diseases. Additionally, he was the medical director of the United Planning Organization’s (UPO) Comprehensive Treatment Program from its inception in 2000 thru October 31, 2012, a multifaceted, non-profit, 500+ slot drug treatment center (methadone replacement therapy) in Washington, DC as a contracted agent of the District of Columbia’s Health Department through the Addiction Prevention and Recovery Agency (APRA). Dr. Chapman and the UPO clinic were featured in the National Alcohol and Drug Addiction Month 2008 DVD entitled “Medication-Assisted Therapies: Providing a Whole-Patient Approach to Treatment” sponsored and produced by the Substance Abuse and Mental Health Services Administration (SAMHSA). Dr. Chapman has kept his hands on the pulse of local and national community issues, particularity those that result in preventable health

disparities in the community around his office (Trinidad and Rosedale) and the African American Community in general. As a founding member and secretary of the board of directors of the Leadership Council on Healthy Communities (501 c3 with 30+ inter faith institutions) chaired by Rev. Frank Tucker, he has been keenly interested in exploring new ways to collaborate and deliver health care to disadvantaged and underserved communities with a focus on building closer ties between medical practitioners and like-minded community partner organizations. Therefore, recognizing a community crisis, Dr. Chapman has focused his energies as an active member of the medical committee of the Washington, DC and Vicinity Affiliate of The National Black Leadership Commission on AIDS as they advocate for public policies that break the vicious cycle of illicit drugs, crime, and incarceration in exacerbating the HIV/AIDS and Hepatitis C epidemics. To that end, he was an expert medical panelist on the June 17, 2011 C-SPAN presentation from the National Press Club sponsored by the Institute of the Black World 21st Century, “Declaring War on the War on Drugs” which also included national experts in social work, criminal justice, law enforcement, public policy, as well as the NAACP. Feature speakers for the event were the Rev. Jessie Jackson, Sr. and Michigan congressman, the Hon. John Conyers.

HOWARD UNIVERSITY COLLEGE OF PHARMACY

PHARMACY POLICY SYMPOSIUM

Tuesday, March 22nd, 2016 8 a.m.

Armour J. Blackburn Center

To further his interest and pursuit of these goals he rejoined the faculty of the Howard University College of Medicine as an adjunct assistant professor in the Department of Psychiatry and Behavioral Health chaired by Professor William B. Lawson, MD, PhD, DLFAPA, bringing an understanding that behavioral health, both mental and spiritual, often predates physical illness, determines physical wellbeing, and often predicates health outcomes. This partnership has produced three innovative grant proposals over the past 1 year including: (1) the Howard University “12 Cities HIV/AIDS Initiative” (focusing on the TANF population at risk for AIDS), (2) SAMHSA “Minority AIDS Continuum of Care Integration of Behavioral Health and Primary Care Pilot” (merging high risk mentally challenged, substance abusers into co-located primary care), and (3) Howard University “Urban Health Institute Demonstration Project” (a holistic family centered approach to treating victims of opiate dependency).

Dr. Chapman received his B.S. from Howard University in 1969 and M.D. from Howard University College of Medicine in 1973. From 1974-1978, he completed his internship, residency in internal medicine, and fellowship in cardiology from the historic Freedmen’s Hospital, then Howard University Hospital in Washington, DC. He is board certified by the American Board of Internal Medicine (ABIM, 1979) and the American Society of Addiction Medicine (grandfathered to ABAM, 2009) and has active memberships in the National Medical Association (NMA), Medico Chirurgical Society of Washington, DC MED CHI of DC), and the American Society of Addiction Medicine (ASAM). Dr. Chapman was previously featured at www.Destiny-Pride.org as the July 2010 spotlight of the month.

SANDRA MILLIGAN, MD, JD SENIOR VICE PRESIDENT AND HEAD OF GLOBAL REGULATORY AFFAIRS AND CLINICAL SAFETY, MERCK & CO.

Sandra A. Milligan, MD, JD, currently serves as Senior Vice President and

Head of Global Regulatory Affairs and Clinical Safety of Merck, consisting

of the global Regulatory, Safety and CMC functions of Merck Research

Laboratories. She previously served as Vice President, Global Regulatory,

Immunology, Respiratory, Infectious Diseases and Ophthalmology for

Genentech/Roche where she developed and directed global strategic

regulatory plans to facilitate and optimize product development,

regulatory approval, and commercialization. Previous to

Genentech/Roche she served at Amgen for almost 10 years in various

roles, including Global Regulatory Therapeutic Area Head for the Bone

franchise, as Head of Regulatory Communications Strategy & Operations,

and as Senior Counsel for the Development, Regulatory & Compliance Law

Group, where she provided strategy for development, regulatory and

safety groups. In addition to serving on the DIA Board of Directors and

current President-Elect, Sandra has served as the Program Chair for the

DIA 2013 Annual Meeting in Boston, as well as co-chair of the Public

Policy/Health Care Compliance/Regulatory Law Annual Meeting track.

Sandra is a graduate of The George Washington University School of

Medicine and the Georgetown University Law Center and attended UC

Irvine for undergraduate studies

BARBARA LOPEZ KUNZ GLOBAL CHIEF EXECUTIVE, DIA

Barbara Lopez Kunz is a health care executive with a successful track

record in leadership positions for socially responsible organizations. In

her current role as Global Chief Executive of DIA (Drug Information

Association), she is leading the transformation of the association through

a systematic strategy impacting global positioning, thought leadership,

strategic partnerships, and member and volunteer engagement. In

Barbara’s prior role as President of Battelle’s Global Health and Life

Science business, she reengineered the business and, through strategic

investments, alliance development, and technology commercialization,

delivered the highest rates of growth in Battelle’s 80-year history.

Barbara’s leadership experience also includes roles as Senior Vice

President and General Manager for Thermo Fisher Scientific’s Biosciences

business, where she championed the unit’s formation and growth

through a series of acquisitions, and Vice President, Latin America and

Global Vice President, Enterprise Business Group for the ICI portfolio businesses. She has also held senior roles in DuPont

and PPG Industries, after starting her career as a research scientist. She holds 14 patents.

A leader on numerous corporate and non-profit boards, Barbara has been heavily involved in governance as chair of the

board The Ohio State University Wexner Medical Center; as director and leader of board subcommittees on technology

commercialization and finance for Nationwide Children’s Hospital Research Institute, Children’s National Health System

Research Institute, and BioOhio; board director for Levitronix and POCARED, medical device companies; director for

Aptevo Therapeutics, an immuno-oncology company, and representative director for International Scientific Standards, a

joint venture in South Korea. She is an active supporter of children’s health, serving on the inaugural board of the

Childhood League School, addressing needs of developmentally challenged children.

Barbara holds an MS in Polymer Science from the University of Akron, a BS from Thiel College, and has qualified in INSEAD’s

International Executive program.

DONALD DOWNING, PHARM.D. CLINICAL PROFESSOR INSTITUTE FOR INNOVATIVE PHARMACY PRACTICE UNIVERSITY OF WASHINGTON SCHOOL OF PHARMACY

Don Downing is a Clinical Professor at the University of Washington

School of Pharmacy in Seattle where he is the endowed Chair of the

Institute for Innovative Pharmacy Practice. He teaches students and

practicing pharmacists in contraception, leadership and advocacy,

medication management services, law & ethics, medical devices,

community health screening of elders and immigrant populations,

and pharmacy management. Currently he is co-chair of his school’s

community pharmacy residency program. Several of Mr. Downing’s

research and healthcare access projects have resulted in national

changes in pharmacy practice. All pharmacies in the US who provide

direct contraception or immunization access have used legislative

efforts and training programs that helped to pioneer. In 2002 he was

awarded the Washington State Pharmacists Association’s

Pharmacist of the Year Award and also the University of Washington

School of Pharmacy’s Alumni of the Year. In 2005 he was awarded

the American Pharmacists Association’s Academy of Pharmacy

Practice and Management Distinguished Achievement Award for his

efforts in innovative public health endeavors. In 2008 he also

received Special Congressional Recognition from Nancy Pelosi for

his community service. In 2009 the Washington State Pharmacy

Association award him the David Almquist Award for his work in

gaining state-wide recognition of pharmacists as healthcare

providers. In 2011, the University of Washington School of

Pharmacy awarded him the Gilbaldi Excellence in Teaching Award

HON. ARTHUR L. BURNETT SR., ESQ (RETIRED) NATIONAL EXECUTIVE DIRECTOR, NATIONAL AFRICAN AMERICAN DRUG POLICY COALITION, INC.

Judge Arthur L. Burnett, Sr. (Retired) is the National Executive Director, National African American Drug Policy Coalition, Inc. He is a graduate from Howard University summa cum laude with a major in political science and minor in economics. Throughout his almost 57-year professional career, he has received numerous awards including the Sustained Superior Performance Award while working with then Attorney General Robert F. Kennedy, the Distinguished Civil Service Award for his work in advising the old U.S. Civil Service Commission and the President of the United States in securing the passage of the Civil Service Reform Act of 1978, recognition by the American Bar Association’s National Conference of Special Court Judges as the Most Outstanding Special Court Judges in America, recognition by the American Bar Association’s National Conference of State Trial Court Judges as one of the three (3) Most Outstanding General Jurisdiction Judges while serving on the District of Columbia Superior Court, the American Bar Association’s Spirit of Excellence Award and acknowledgement as a WAYMAKER in the American Bar Association Judges’ Journal for his civil rights history and judicial performance in an extensive interview of his life’s history, and recognition by Cambridge’s Who’s Who as one of the most knowledgeable experts in the United States on the drug laws and policies of this Nation and the application of the criminal and juvenile justice system and related healthcare issues involving treatment for substance use disorders and

mental health conditions. He retired completely from the judiciary on February 15, 2013 and continues to serve as the National Executive Director of the National African American Drug Policy Coalition, Inc. and as a citizen volunteer advisor to several offices in the White House and to a number of Federal Government Departments and Agencies. In addition, he was recently appointed by the Mayor of the District of Columbia to a part-time position as a Member of the District of Columbia Commission on Fathers, Men and Boys. He also serves on a number of other non-profit entities dealing with youth, substance abuse, mental health conditions, and juvenile and criminal justice issues.